Direct Access to High-Purity Synthesized Peptides, Specialized Fine Chemicals, and Pharmaceutical Raw Materials
In the rapidly evolving landscape of mRNA therapeutics, targeted therapeutics, and advanced peptide chemistry, high-purity nucleosides—specifically Pseudouridine (CAS 1445-07-4) and its methylated derivative N1-Methylpseudouridine (CAS 1428903-59-6)—serve as critical critical building blocks. As premier China Uridine Pseudouridine Suppliers & Manufacturers, Gentolex leverages standard-setting infrastructure spanning a 250,000 square meter construction footprint to deliver commercial-scale modified nucleosides, peptide APIs, and specialized custom synthesis.
Incorporating modified nucleosides into synthetic mRNA transcripts is essential for bypassing innate cellular immune surveillance systems, notably Toll-like receptors (TLR3, TLR7, and TLR8). Chemical substitution of standard uridine with pseudouridine enhances RNA structural stability, boosts ribosomal translation capacity, and substantially diminishes unintended immunogenicity. Gentolex operates at the forefront of this biomanufacturing revolution, delivering scalable bulk quantities with complete batch-to-batch consistency and regulatory compliance support.
Traditional multi-step chemical synthesis of Pseudouridine involves intricate C-glycosidic bond formation, often requiring rigorous protecting group manipulations. Next-generation technology roadmaps at Gentolex emphasize hybrid chemo-enzymatic routes. By engineering high-throughput recombinant tRNA pseudouridine synthases (TruB / RluA enzymes), production cycles achieve higher stereo-selectivity, lower carbon footprints, and eliminate hazardous organometallic residues.
While unmodified Pseudouridine (Ψ) introduced a paradigm shift in RNA stability, N1-Methylpseudouridine (m1Ψ) has emerged as the definitive global gold standard for commercial mRNA therapeutics. Chemical methylation at the N1 position further dampens PKR (protein kinase R) activation, increases translational capacity by up to 4-fold in human primary cells, and minimizes cellular toxicities during high-dose systemic administration.
The future of genetic medicine demands modified nucleosides optimized for circular RNA (circRNA) backbones and self-amplifying mRNA (saRNA) constructs. Gentolex R&D is aggressively expanding synthesis vectors into modified nucleoside triphosphates (NTPs), phosphoramidites, and customized ribose-modified analogs (e.g., 2'-O-methylated derivatives) to support next-generation circRNA stability and targeted lipid nanoparticle (LNP) packaging.
| Modified Nucleoside Compound | CAS Registry No. | Primary Biological Mechanism | Translation Efficiency Impact | cGMP Scalability Standard |
|---|---|---|---|---|
| Uridine (Standard) | 58-96-8 | Native RNA pyrimidine base | Baseline (High Immunogenicity) | Metric Ton Commercial Scale |
| Pseudouridine (Ψ) | 1445-07-4 | C-Glycosidic isomer; suppresses TLR7/8 | Enhanced (+150-200%) | Multi-Kilogram & Metric Ton |
| N1-Methylpseudouridine (m1Ψ) | 1428903-59-6 | N1-Methylated isomer; abolishes PKR binding | Maximal (+300-400%) | Commercial cGMP Batch Standard |
| 5-Methoxyuridine (5moU) | 7481-88-1 | 5-Position substitution; reduces innate sensing | High (+200-250%) | Custom R&D & Semi-Bulk Scale |
Infectious disease targets mandate rapid turnaround from sequence design to bulk formulation. Gentolex supplies IVT-grade (In Vitro Transcription) Pseudouridine and N1-Methylpseudouridine triphosphates with ultra-low trace heavy metals, ensuring zero inhibition of T7 RNA Polymerase during high-density transcription reactions.
Personalized cancer vaccines rely on high-fidelity mRNA expressing specific tumor neoantigens. Our pure modified nucleosides prevent aberrant cytokine storms in systemic oncology protocols while ensuring robust antigen expression within dendritic cells and antigen-presenting systems.
Transient expression of Cas9/Cas12 endonuclease mRNA requires strict control over off-target immune activation. Utilizing Gentolex’s GMP-grade Pseudouridine derivatives guarantees stable, high-yield Cas protein translation, enabling precise genomic modification with minimum cytotoxic cellular stress.
Gentolex has transformed traditional chemical manufacturing by building an internationally compliant standard production infrastructure encompassing over 250,000 square meters. Operating under strict Industry 4.0 principles, our automated synthesis facilities combine continuous flow reactors, real-time Process Analytical Technology (PAT), and machine-learning-assisted crystallization controls.
In-line HPLC and Raman spectroscopy monitor intermediate formation during nucleoside C-glycosylation and N1-methylation in real time. This minimizes impurities like unreacted uridine or regional isomers, maintaining automated purity thresholds >99.5%.
By integrating key raw material sourcing—from basic ribose derivatives to specialized pyrimidine bases—within China’s comprehensive chemical ecosystem, Gentolex offers global pharmaceutical partners up to 40% cost efficiency over legacy Western manufacturers without compromising quality.
With dedicated logistics hubs and established corporate representative offices in key territories such as Mexico and South Africa, Gentolex guarantees cold-chain shipping (-20°C and cold transport) with full temperature data-logging and seamless customs clearances worldwide.
All Pseudouridine and peptide synthesis operations adhere rigidly to international cGMP (Current Good Manufacturing Practice) guidelines and ISO 9001:2015 / ISO 14001 certification. Analytical testing is executed in certified QC laboratories equipped with Agilent, Waters, and Thermo Fisher instrumentation.
Gentolex assists global clients in navigating international regulatory bodies (US FDA, EMA, NMPA, PMDA). We provide fully accessible Drug Master Files (DMF), Certificates of Analysis (CoA), Stability Data (ICH Q1A-Q1F), and BSE/TSE-free certification for commercial product filings.
We welcome virtual and physical site audits by client quality control teams. Complete batch production records (BPRs), equipment validation logs, and change control procedures are transparently documented to guarantee rapid client approval pathways.
Gentolex’s goal is to create opportunities connecting the world with better services and guaranteed products. Up to date, Gentolex Group has been serving customers from more than 10 countries, specially, representatives are established in Mexico and South Africa. Our main services focus on supplying peptides APIs and Custom Peptides, FDF license out, Technical Support & Consultation, Product Line and Lab Setup, Sourcing & Supply Chain Solutions.
Our main services focus on supplying peptides APIs and Custom Peptides, FDF license out, Technical Support & Consultation, Product Line and Lab Setup, Sourcing & Supply Chain Solutions.
An overall factory construction area of 250,000 square meters under international standard to offer flexible, scalable and cost-effective solutions.
Gentolex offers an extensive range of APIs and intermediates for development study and commercial application with cGMP standard from long-term collaborations. Documents and Certificates are supported to customers worldwide.
Continuous technical development, enzymatic synthesis platform expansion, and innovative pathway optimization for modified nucleosides and biological active ingredients.
For those clients who prefer to avoid the complexity of dealing with multiple points of contact, we provide extra customized procurement services with the most superior and comprehensive supply chain sources.
Clients provide exact purity requirements, impurity thresholds (e.g., individual unknown <0.05%), endotoxin specifications, and physical characterization needs (powder particle size, water content via Karl Fischer).
Gentolex provides qualified analytical sample kits complete with High-Performance Liquid Chromatography (HPLC) spectrums, Proton NMR (1H-NMR), Mass Spectrometry (MS), and Certificate of Analysis (CoA) validation.
Upon sample qualification, multi-kilogram to metric-ton production batches are initiated in dedicated reactor suites, executing strict continuous monitoring and complete traceability.
Products are sealed under inert nitrogen atmosphere in double thermal bags, housed in insulated protective shipping containers, and dispatched via express air freight under dynamic GPS and temperature monitoring.
Introduction to Selank Acetate API Selank Acetate API is a synthetic heptapeptide active pharmaceutical ingredient (API) composed of the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). Originally developed through neuropharmacological research, Selank is a derivative of the endogenous...
View Details
Trusted Thymosin Beta-4 API Manufacturer and Global Peptide Supplier As a professional Thymosin Beta-4 API manufacturer and supplier, we provide high-quality Thymosin Beta-4 peptide API solutions for biotechnology companies, pharmaceutical research organizations, and li...
View Details
Introduction BPC-157 API is a synthetic pentadecapeptide that has gained increasing attention in peptide research due to its potential biological activities related to tissue repair, gastrointestinal protection, angiogenesis, and inflammatory regulation. As a peptide ac...
View Details
With the continuous development of neuroscience, peptide technology, and life science research, neuroactive peptides have become an important area of scientific investigation. Semax, a synthetic peptide derived from an ACTH fragment, has attracted attention among researchers due to its unique mol...
View Details
SS-31 API, also known as Elamipretide, MTP-131, Bendavia, and SS31, is a synthetic mitochondria-targeting tetrapeptide designed to bind cardiolipin in the inner mitochondrial membrane. By stabilizing mitochondrial structure and supporting cellular bioenergetics, SS-31 ha...
View DetailsGentolex supplies Pseudouridine and N1-Methylpseudouridine with standard purity levels of ≥ 99.0% to ≥ 99.5% as determined by High-Performance Liquid Chromatography (HPLC). For IVT and enzymatic therapeutic applications, single individual unknown impurities are strictly controlled under < 0.1%, with heavy metal content guaranteed below 5 ppm.
Standard Uridine triggers endosomal immune receptors (TLR7 and TLR8), leading to potent inflammatory responses and translation arrest. Substituting Uridine with N1-Methylpseudouridine evades immune sensing, markedly increases mRNA half-life in physiological conditions, and enhances target protein expression efficiency by up to several fold.
Backed by our 250,000 m² modern manufacturing footprint, Gentolex accommodates initial R&D sampling (gram scale), clinical trial batches (kilogram scale), and commercial volume requirements reaching multi-metric-ton supply commitments with complete batch-to-batch traceability.
Every shipment includes a detailed Certificate of Analysis (CoA), 1H-NMR spectrum, HPLC chromatogram, Mass Spectrometry (MS) analysis, Material Safety Data Sheet (MSDS), and TSE/BSE Statement. Drug Master Files (DMF) and ICH stability testing documentation are available upon execution of standard supply agreements.
Endotoxin levels are verified via Chromogenic LAL testing to ensure strict compliance below 0.01 EU/mg. Special ultra-pure endotoxin-free water systems and pyrogen-controlled reaction environments are utilized during final purification and packaging stages.
Pseudouridine and its methylated triphosphates/nucleosides should be stored long-term at -20°C or -80°C under dry, desiccated, light-protected conditions. Avoid repeated freeze-thaw cycles by reconstituting materials into single-use aliquot portions inside sterile, RNase-free environments.
Explore Gentolex's Comprehensive Catalog of Peptides, Active APIs, and Fine Chemical Intermediates
